A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia

BACKGROUND: Dyslipidemia is one of the most frequently implicated risk factors for development of atherosclerosis. This study evaluated the efficacy of amla (Emblica officinalis) extract (composed of polyphenols, triterpenoids, oils etc. as found in the fresh wild amla fruit) in patients with dyslip...

Descripción completa

Detalles Bibliográficos
Autores principales: Upadya, Haridas, Prabhu, S., Prasad, Aravinda, Subramanian, Deepa, Gupta, Swati, Goel, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341673/
https://www.ncbi.nlm.nih.gov/pubmed/30670010
http://dx.doi.org/10.1186/s12906-019-2430-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341673/
https://www.ncbi.nlm.nih.gov/pubmed/30670010
http://dx.doi.org/10.1186/s12906-019-2430-y

Ejemplares similares